Carcinoembryonic Antigen in the Staging and Follow-up of Patients with Colorectal Cancer

Goldstein, Mitchell; Mitchell, Edith P.

doi:10.1081/cnv-200058878

Cited by 93 publications

(117 citation statements)

References 0 publications

Supporting

Mentioning

108

Contrasting

Unclassified

Order By: Relevance

“…In the present study, significant increases in serum concentrations of CEA and CA 19-9 in patients with colorectal and gastric cancers could provide powerful and useful information regarding the progression of these specific types of cancer, consistent with other reports (30)(31)(32)(33). Although the serum levels of MMP-9, 130-and 225-kDa gelatinolytic bands showed statistical significance similar to that exhibited by conventional tumor markers such as CEA and CA 19-9, none of them significantly correlate with CEA or CA 19-9 expression in serum.…”

Section: Discussionsupporting

confidence: 92%

Serum levels of matrix metalloproteinase-2 and -9 and conventional tumor markers (CEA and CA 19-9) in patients with colorectal and gastric cancers

Emara

Cheung

Grabowski

et al. 2009

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

Background: Matrix metalloproteinases (MMPs), especially MMP-2 and MMP-9, play an important role in tumor invasion and metastasis. This study aimed to determine the serum levels of MMP-2, MMP-9, 130-and 225-kDa gelatinolytic bands and conventional tumor markers, carcinoembryonic antigen (CEA) and cancer antigen (CA) 19-9, in patients with gastrointestinal cancers. The relationship between these parameters and clinicopathological factors was also studied. Methods: Sera from controls (ns19), and patients with colorectal (ns47) and gastric (ns34) cancer were collected prospectively. The gelatinolytic activities of MMP-2, MMP-9, 130-and 225-kDa bands were determined using gelatin zymography. CEA and CA 19-9 were determined using immunoradiometric assay (IRMA). Results: Serum levels of MMP-9, 130-and 225-kDa gelatinolytic bands, CEA, and CA 19-9, but not MMP-2, in colorectal and gastric cancer were significantly higher than that of controls. No significant correlation was found between histological grade or clinical stage and levels of MMP-9, 130-and 225-kDa gelatinolytic bands, which were correlated (rs0.61-0.89, p-0.005). Conclusions: Our findings suggest that zymographic determination of

show abstract

Section: Discussionsupporting

confidence: 92%

Serum levels of matrix metalloproteinase-2 and -9 and conventional tumor markers (CEA and CA 19-9) in patients with colorectal and gastric cancers

Emara

Cheung

Grabowski

et al. 2009

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

show abstract

“…As many colorectal cancer patients have high levels of soluble CEA protein in their serum ( Goldstein and Mitchell, 2005), an antibody may be less effective in those patients. We studied whether soluble CEA inhibited the function of MEDI-565.…”

Section: Discussionmentioning

confidence: 99%

Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody

Osada

Hsu

Hammond³

et al. 2009

Br J Cancer

View full text Add to dashboard Cite

BACKGROUND: Novel technologies to redirect T-cell killing against cancer cells are emerging. We hypothesised that metastatic human colorectal cancer (CRC) previously treated with conventional chemotherapy would be sensitive to T-cell killing mediated by carcinoembryonic antigen (CEA)/CD3-bispecific T-cell-engaging BiTE antibody (MEDI-565). METHODS: We analysed proliferation and lysis of CEA-positive (CEA þ ) CRC specimens that had survived previous systemic chemotherapy and biologic therapy to determine whether they could be killed by patient T cells engaged by MEDI-565 in vitro. RESULTS: At low concentrations (0.1 -1 ng ml À1 ), MEDI-565 þ T cells caused reduced proliferation and enhanced apoptosis of CEA þ human CRC specimens. High levels of soluble CEA did not impair killing by redirected T cells and there was no increase in resistance to T-cell killing despite multiple rounds of exposure. CONCLUSIONS: This study shows for the first time that metastatic CRC specimens derived from patients previously treated with conventional chemotherapy can be lysed by patient T cells. Clinical testing of cancer immunotherapies, such as MEDI-565 that result in exposure of tumours to large numbers of T cells, is warranted.

show abstract

“…The three factors represented different pathways: GGT was thought as correlated with cellular defense and contributing to drug resistance (Franzini et al, 2006), CEA was correlated with the invasion and metastasis of tumor cells (Goldstein and Mitchell, 2005;Yang et al, 2011) while NLR was thought as represent an unfavorable tumor microenvironment . The model based on three factors may represent a more comprehensive understanding to tumors thus was superior to two factors.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Model Built on Blood-based Biomarkers in Patients with Metastatic Colorectal Cancer

Jiang²,

Yin

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: We had previously showed that the neutrophil lymphocyte ratio (NLR), γ-glutamyl transpeptidase (GGT) and carcinoembryonic antigen (CEA) are prognostic factors for metastatic colorectal cancer (mCRC) patients. In this study we developed a prognostic model based on these three indices. Materials and Methods: A total of 243 patients who were initially diagnosed as mCRC between 2005 and 2010 in the Sun Yat-sen University Cancer Center were studied. The endpoint was overall survival (OS). Results: NLR>3, elevated GGT and elevated CEA were confirmed as independent risk factors which could predict poor prognosis. Patients could be divided into three groups according to the number of risk factors they had. Those with two or three were defined as the high risk group, individuals with one risk factor as the modest risk group and patients without risk factor as the low risk group. The OS values for these three groups were 16.2 months (2.80~68.8), 24.2 months (4.07~79.0), and 37.2 months (12.6~87.8), respectively (p<0.001). Conclusions: We developed a simple but useful model based on NLR, GGT and CEA to provide prognostic information to clinical practice in highly selected mCRC patients. Further prospective and multi-center studies are warranted to test our model.

show abstract

Carcinoembryonic Antigen in the Staging and Follow-up of Patients with Colorectal Cancer

Cited by 93 publications

References 0 publications

Serum levels of matrix metalloproteinase-2 and -9 and conventional tumor markers (CEA and CA 19-9) in patients with colorectal and gastric cancers

Serum levels of matrix metalloproteinase-2 and -9 and conventional tumor markers (CEA and CA 19-9) in patients with colorectal and gastric cancers

Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody

Prognostic Model Built on Blood-based Biomarkers in Patients with Metastatic Colorectal Cancer

Contact Info

Product

Resources

About